Vascular Endothelial Growth Factor Receptor 3 (FLT4) Antibody
383.5€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Vascular Endothelial Growth Factor Receptor 3 (FLT4) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx012107
tested applications
ELISA
Description
This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. Tissue specificity: Placenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain. VEGFR-3 is induced in all endothelial cells (EC’s) during early embryogenesis, and its expression eventually disappears from the vascular endothelial cells of adult tissues. VEGFR-3 is constitutively expressed in the adult lymphatic endothelium. Although VEGFR-3 is not expressed in adult blood vessels, it is induced in vascular endothelial cells of tumor-bearing tissues.VEGFR-3 expression in adults is largely restricted to the endothelial cells of the lymphatic system, and high endothelial venules (HEV).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Vascular Endothelial Growth Factor Receptor 3 (FLT4) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | ELISA: 1/10000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG1 |
| Purification | Unpurified ascites. |
| Size 1 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA |
| Buffer | Ascitic fluid containing 0.03% sodium azide. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P35916 |
| Gene ID | 2324 |
| OMIM | 136352 |
| Alias | PCL,CHTD7,FLT-4,FLT41,LMPH1A,LMPHM1,VEGFR3,VEGFR-3,Tyrosine-protein kinase receptor FLT4,Fms-like tyrosine kinase 4,Vascular endothelial growth factor receptor 3 |
| Background | Antibody anti-FLT4 |
| Status | RUO |
| Note | Concentration: Not determined. - |
Descripción
Fms related receptor tyrosine kinase 4 (FLT4) FLT4, also known as vascular endothelial growth factor receptor 3 (VEGFR3), is a receptor tyrosine kinase critical for the regulation of lymphangiogenesis, the formation of lymphatic vessels. Structurally, FLT4 comprises an extracellular domain with seven immunoglobulin-like loops, a single transmembrane domain, and an intracellular tyrosine kinase domain. FLT4 binds VEGF-C and VEGF-D ligands, leading to receptor dimerization and activation of downstream signaling pathways, including the MAPK and PI3K-AKT cascades. These pathways are essential for lymphatic endothelial cell proliferation, migration, and survival. FLT4 is predominantly expressed in lymphatic endothelial cells, where it plays a pivotal role in maintaining lymphatic vessel integrity and fluid homeostasis. Dysregulation of FLT4 has been linked to lymphedema, a condition characterized by lymphatic fluid accumulation, and its overexpression has been implicated in cancer progression, where it promotes tumor lymphangiogenesis and metastasis. FLT4 is a promising therapeutic target for modulating lymphatic function in both pathological and developmental contexts.
Related Products
Human FLT4 (Vascular endothelial growth factor receptor 3) ELISA Kit
Ver Producto
Mouse VEGFR3/FLT4 (Vascular Endothelial Cell Growth Factor Receptor 3) ELISA Kit
Ver Producto